Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.61 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.61 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.59 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.54 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.48 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582480 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL666363 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL22556278 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL19878648 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL6829952 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL28722720 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL31096006 | 0.97 | PLA2G2C (0.61) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL28927332 | 0.95 | PLA2G2C (0.59) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL28927329 | 0.95 | PLA2G2C (0.59) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL25394384 | 0.93 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 929 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636252-B2 | Process of preparing mRNA-loaded lipid nano particles | TRANSLATE BIO, INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260115221-A1 | SYNERGISTIC ENHANCEMENT OF THE DELIVERY OF NUCLEIC ACIDS VIA BLENDED FORMULATIONS | TRANSLATE BIO INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4637813-A1 | RHINOVIRUS MRNA VACCINE | Sanofi Pasteur (FR) | 2025-10-29 | — | — | EP | claimed |
| US-12453739-B2 | Synergistic enhancement of the delivery of nucleic acids via blended formulations | TRANSLATE BIO, INC. (US) | 2025-10-28 | — | — | US | claimed |
| EP-4633673-A1 | MRNA ENCODING INFLUENZA VIRUS-LIKE PARTICLE | Sanofi Pasteur Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4619378-A2 | IONIZABLE LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS FOR THE DELIVERY OF NUCLEIC ACIDS | Seawolf Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4614148-A2 | SYNERGISTIC ENHANCEMENT OF THE DELIVERY OF NUCLEIC ACIDS VIA BLENDED FORMULATIONS | Translate Bio, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250268994-A1 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | TRANSLATE BIO, INC. (US) | 2025-08-28 | — | — | US | claimed |
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2012-03-15 | — | — | US | claimed |
| US-20100062967-A1 | COATED LIPID COMPLEXES AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2010-03-11 | — | — | US | claimed |
| WO-2006069782-A9 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2009-04-30 | — | — | WO | claimed |
| US-20090074852-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | SILENCE THERAPEUTICS AG (DE) | 2009-03-19 | — | — | US | claimed |
| EP-2007356-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | Silence Therapeutics AG (DE) | 2008-12-31 | — | — | EP | claimed |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | SILENCE THERAPEUTICS AG (DE) | 2008-11-06 | — | — | US | claimed |
| JP-2007536324-A | — | — | 2007-12-13 | — | — | JP | claimed |
| WO-2007121947-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | SILENCE THERAPEUTICS AG. (DE) | 2007-11-01 | — | — | WO | claimed |
| EP-1771206-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | atugen AG (DE) | 2007-04-11 | — | — | EP | claimed |
| WO-2005105152-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | ATUGEN AG (DE) | 2005-11-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074852-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | LIPG, LIPA, PHOSPHO1 | PLA2G2C 83/4885LPAR1 11/4885LPAR3 20/4885 |
| US-12453739-B2 | Synergistic enhancement of the delivery of nucleic acids via blended formulations | HNRNPAB, FABP1, SNRPE | PLA2G2C 296/4885LPAR1 123/4885LPAR3 143/4885 |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | SMN1; SMN2, CDR2, ATXN2 | PLA2G2C 423/4885LPAR1 1527/4885LPAR3 1093/4885 |
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, SGMS1 | PLA2G2C 470/4885LPAR1 34/4885LPAR3 39/4885 |
| US-12636252-B2 | Process of preparing mRNA-loaded lipid nano particles | RNMT, SOAT2, METTL16 | PLA2G2C 919/4885LPAR1 967/4885LPAR3 1018/4885 |
| US-20100062967-A1 | COATED LIPID COMPLEXES AND THEIR USE | HDLBP, NR1H3, CETP | PLA2G2C 326/4885LPAR1 69/4885LPAR3 108/4885 |
| US-20260115221-A1 | SYNERGISTIC ENHANCEMENT OF THE DELIVERY OF NUCLEIC ACIDS VIA BLENDED FORMULATIONS | RNMT, PLTP, CHMP4B | PLA2G2C 453/4885LPAR1 428/4885LPAR3 510/4885 |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | MGLL, LIPA, SGMS1 | PLA2G2C 523/4885LPAR1 32/4885LPAR3 39/4885 |
| US-20250268994-A1 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | ACE2, LNPEP, ACE | PLA2G2C 235/4885LPAR1 747/4885LPAR3 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.